Literature DB >> 34430461

Cutaneous Sarcoidosis: A Retrospective Clinico-Pathological Study from the Indian Subcontinent in Patients Attending a Tertiary Health Care Centre.

Gauri D Mahabal1, Dincy C V Peter1, Leni George1, Meera Thomas2, Susanne A Pulimood1.   

Abstract

CONTEXT: Sarcoidosis is a systemic disorder characterized histologically by noncaseating granulomas. There is paucity of Indian data on cutaneous sarcoidosis. AIMS: To describe the clinical, histopathological findings, and extracutaneous involvement in cutaneous sarcoidosis.
MATERIALS AND METHODS: A retrospective study was done in patients of cutaneous sarcoidosis who had attended the dermatology clinic of a tertiary health care center in India from May 2009 to April 2015. The clinical details, histopathological findings, treatment, and response were reviewed.
RESULTS: There were 38 patients with cutaneous sarcoidosis. Mean age was 48 ± 13 years; 58% were female. Median duration of disease was 11 months (IQR 4-48 months). More than one morphology was seen in 28.9%, commonest being plaques (65.7%), and papules (50%). Erythema nodosum was rare. More than one site was involved in 55.3%, most commonly trunk (52.6%). Six patients had isolated cutaneous sarcoidosis. Commonest extracutaneous organs involved were lung (73.7%) and lymph nodes (68.4%). Histopathologically, classical naked sarcoidal granulomas were found in only 55.3%. Angiotensin converting enzyme (ACE) levels were elevated in 74.3% (26/35) with significant association with extracutaneous disease. Treatment included topical and/or systemic corticosteroids, hydroxychloroquine, and tacrolimus. STATISTICS: Pearson's Chi-square test was done to analyze associations between the skin lesions, ACE levels, and systemic involvement; P < 0.05 was considered significant.
CONCLUSIONS: Cutaneous manifestations of sarcoidosis are varied, commonest being erythematous plaques. Even though most patients had systemic involvement, we found no significant association of the type and number of skin lesions with extracutaneous involvement or prognosis. Elevated ACE levels were significantly associated with systemic involvement. Copyright:
© 2021 Indian Dermatology Online Journal.

Entities:  

Keywords:  ACE levels; naked granulomas; sarcoidosis

Year:  2021        PMID: 34430461      PMCID: PMC8354409          DOI: 10.4103/idoj.IDOJ_606_20

Source DB:  PubMed          Journal:  Indian Dermatol Online J        ISSN: 2229-5178


Introduction

Sarcoidosis is a multisystem disorder of unknown etiology characterized by noncaseating granulomas on histopathology.[1] Skin is the most accessible and second most common organ involved in sarcoidosis.[2] The reported prevalence of cutaneous sarcoidosis is 20–35%.[12] Most of the studies on cutaneous sarcoidosis are from the West with relative paucity of Indian data.[3456] Hence, we undertook this study to describe the clinical and histopathological spectrum of cutaneous sarcoidosis in our population and to look for any association between the various cutaneous lesions, systemic involvement, serum angiotensin converting enzyme (ACE) levels and prognosis.

Subjects and Methods

A retrospective study on cutaneous sarcoidosis between 1 May 2009 to 30 April 2015 (6 years) was conducted in the dermatology department of a tertiary care setting in South India. Patients in whom cutaneous sarcoidosis was clinically suspected and the histopathology showed the presence of epithelioid granulomas were included in the study after exclusion of infective causes like cutaneous tuberculosis, atypical mycobacterial infections, leishmaniasis, and deep fungal infections, by special stains and cultures for bacteria, mycobacteria, and fungi and non-infectious granulomatous conditions like granuloma annulare. Their clinical details, laboratory investigations, and histopathology were reviewed. Histopathologically, sarcoidosis was diagnosed based on non-caseating granulomatous inflammation and the features looked for were type of granulomas, whether naked or non-naked, discrete or confluent, and their location and depth and necrosis, if present.[7] Reticulin and mucin stain, if done, were also reviewed. The symptoms, clinical features, and systemic involvement were noted from the hospital records. Investigations like Mantoux test (performed using 2TU tuberculin), chest radiography, and ACE levels were reviewed. Chest X-ray staging was done based on the Siltzbach classification system.[8] Serum ACE levels more than 52 U/L were taken as elevated. The treatment given and the response to treatment were recorded and classified as complete resolution, persistent lesions, and relapse of lesions.

Statistical methods

Frequencies and percentages were reported for qualitative variables. Pearson's Chi-square test was used to analyze associations between the type and extent of skin lesions with systemic involvement and elevated ACE levels. The P value less than 0.05 was considered as statistically significant. Analysis was done using SPSS version 16.0.

Results

There were 38 patients of cutaneous sarcoidosis during the six-year study period. The patient details are shown in Table 1. Mean age was 48 ± 13 years with a slight female preponderance (58%). Majority (51%) of our patients were from the eastern states, followed by the southern (30%) and north eastern states of India (5.2%), 4 patients from Bangladesh, and 1 from Nepal. More than one anatomical region was involved in 55.2% patients. The sites involved were trunk (52.6%), face (44.7%), and upper limbs (44.7%). Isolated cutaneous sarcoidosis was found in 6 (15.8%) patients. Erythematous plaques (65.7%) [Figure 1a and b] and papules (50%) [Figure 2a and b] were the commonest specific skin lesion seen. Rare cutaneous presentations [Figure 3a and b] were seen in 5 patients (13.1%). Erythema nodosum was seen in only 2 patients (5.2%) and both had lung involvement. Multiple (>3) skin lesions were seen in 28 patients (73.7%). Lungs (73.7%) were the most common extracutaneous organ system involved followed by the lymph nodes (68.4%). The chest X-ray staging was stage 0 in 23.6% (n = 9) patients, stage 1 in 2.6% (n = 1), stage 2 in 63.2% (n = 24), and stage 3 in 10.6% (n = 4). Eye involvement was found in 5 cases of which 3 had uveitis, 1 had conjunctival granulomas, while both uveitis and conjunctival granulomas were noted in 1 patient. Mantoux test was negative in all cases. There was no significant association of systemic involvement and type of skin lesions (p = 0.40) or number of skin lesions (p = 0.13) or of lesions over the face with involvement of the respiratory tract (p = 0.456).
Table 1

Disease characteristics

CharacteristicNumber (%)
Gender
 Male16 (42)
 Female22 (58)
Age (mean +/− SD in years)48 (+/−13)
Age at onset (mean +/− SD in years)46 (+/−13.5)
Duration of disease (median; interquartile range) (in months)11 (4-48)
Type of skin lesion (More than 1 morphology in n=11 (28.9%))
 1. Plaques25 (65.7)
 2. Papules19 (50)
 3. Nodules5 (13.1)
 4. Others (Depigmented macules 2, Psoriasiform 1, Scar 1, Angiolupoid 1)5 (13.1)
 5. Non-specific (Erythema nodosum)2 (5.2)
Number of skin lesions
 1. Up to three lesions10 (26.4)
 2. More than or equal to 4 lesions28 (73.7)
Site of the lesion (More than 1 region involved in n=21 (55.3%))
 1. Torso20 (52.6)
 2. Face17 (44.7)
 3. Upper limb17 (44.7)
 4. Lower limb14 (36.8)
Isolated cutaneous sarcoidosis6 (15.8)
Systemic involvement (more than 1 organ involved in n=29 (76.3%))32 (84.2)
 1. Lungs28 (73.7)
 2. Lymph nodes (thoracic=19, extrathoracic=7)26 (68.4)
 3. Liver7 (18.4)
 4. Spleen5 (13.2)
 5. Eyes5 (13.2)
 5. Others (Neurologic 2, Cardiac 2, bone marrow 1, salivary gland 1)6 (15.7)
ACE levels (n=35)
 ACE levels up to 52 U/L9 (25.7)
 ACE >52 U/L26 (74.3)
Treatment
 Topicals (Steroids±Tacrolimus)38 (100)
 Intralesional steroids1 (2.6)
 Systemic steroids alone15 (39.4)
 Systemic steroids + hydroxychloroquine10 (26.3)
 Hydroxychloroquine alone6 (15.7)
Response to treatment (cutaneous lesions)
 Resolved10 (26.3)
 Improving5 (13.2)
 Persistent3 (7.9)
 Relapsed4 (10.5)
 Lost to follow up16 (42.1)

Values are given as number (%) unless otherwise specified

Figure 1

1(a): Plaque lesions sarcoidosis on the lower limb. 1(b): Annular plaques of sarcoidosis on the face

Figure 2

2(a): Papular lesions of sarcoidosis on the nape of the neck. 2(b): Papular lesions of sarcoidosis on the upper back

Figure 3

3(a): Angiolupoid sarcoidosis. 3(b): Psoriasiform lesions of sarcoidosis on the lower back

Disease characteristics Values are given as number (%) unless otherwise specified 1(a): Plaque lesions sarcoidosis on the lower limb. 1(b): Annular plaques of sarcoidosis on the face 2(a): Papular lesions of sarcoidosis on the nape of the neck. 2(b): Papular lesions of sarcoidosis on the upper back 3(a): Angiolupoid sarcoidosis. 3(b): Psoriasiform lesions of sarcoidosis on the lower back Elevated ACE levels were found in 74.3% (26/35) of those tested and were significantly associated with systemic involvement (p = 0.00) (especially lung involvement [p = 0.00] and lymph node involvement [p = 0.013]). All the patients with isolated cutaneous sarcoidosis were found to have normal ACE levels.

Histopathology

Table 2 illustrates comparison of histopathological findings with other studies. Naked granulomas [Figure 4a] were found in 55.3% (n = 21), while non-naked granulomas in 44.7% (n = 17). Cutaneous lesions in patients with non-naked granulomas included papules and plaques (n = 3), only plaques (n = 7), papules (n = 4), papules and plaques with depigmented lesions (n = 1), angiolupoid lesion (n = 1), and subcutaneous nodule (n = 1). Rare clinical presentations like depigmented lesions with plaques (n = 1), psoriasiform (n = 1), and scar (n = 1) showed naked granulomas. Perineural location of granulomas with special stains being negative for acid fast lepra bacilli was seen in 1 patient. Fibrinoid necrosis was seen in 15.7% (n = 6) and multinucleated giant cells [Figure 4b] in 94.7%. Foreign bodies were found in only 5 cases, under non-polarizing microscope. Reticulin staining [Figure 4c] was done in 23 patients, of which it was preserved or increased in 19 (82%). There was no clinicopathological correlation with systemic features.
Table 2

Histopathological findings in our study and comparison with other studies

Histopathological findingOur studyBall et al., 2004[19]Cardoso et al., 2009[18]Mangas et al., 2006[9]Ishak et al., 2014[13]García-Colmenero et al., 2019[16]
Number of specimens examined382831428148
Type of granulomas
Naked granulomas21 (55.3)25 (89)22 (71)30 (71)81 (100)48 (100)
 Naked (discrete)13
 Naked (confluent)5
 Naked (discrete + confluent)3
 Non-naked (discrete)6
 Non-naked (confluent)5
 Non-naked (discrete + confluent)6
Depth of granulomas
 Superficial11 (29)5 (16)4 (5)21 (43.8)
 Mid dermis10 (26.4)9 (29)9 (11)
 Deep dermis8 (21)17 (54)65 (80)34 (70.8)
 Subcutis9 (23.6)0 (0)16 (20)2 (41.7)
Distribution of granulomas
 Non-specific/Interstitial19 (50)17 (51)34 (83)27 (33)
 Perineural1 (2.6)7 (25)4 (13)15 (23)6 (12.5)
 Periadnexal8 (21)10 (32)8 (19)13 (16)15 (31.3)
 Perivascular9 (23.6)4 (13)54 (66)24 (50)
Associated inflammatory cells seen
 Neutrophils3 (7.8)7 (25)
 Eosinophils09 (32)
 Plasma cells12 (31.5)10 (36)
Multinucleate giant cells36 (94.7)28 (100)30 (97)90%46 (95.8)
Foreign bodies5 (13.1)15 (53)10 (32)11 (26)1 (2)
Necrosis6 (15.7)12 (43)2 (6)4 (9)1 (1)13 (27)
Mucin2 (5.2)5 (18)
Reticulin19/23

Values are given as number (%) unless otherwise specified

Figure 4

4(a): Multiple discrete naked granulomas (Hematoxylin and Eosin stain, 5×). 4(b): Granuloma with a multinucleate cell and ill-formed asteroid body (arrow), (Hematoxylin and Eosin stain, 400×). 4(c): Preserved reticulin fibers within the granuloma (Reticulin stain, 100×)

Histopathological findings in our study and comparison with other studies Values are given as number (%) unless otherwise specified 4(a): Multiple discrete naked granulomas (Hematoxylin and Eosin stain, 5×). 4(b): Granuloma with a multinucleate cell and ill-formed asteroid body (arrow), (Hematoxylin and Eosin stain, 400×). 4(c): Preserved reticulin fibers within the granuloma (Reticulin stain, 100×)

Treatment

Topical steroids with or without tacrolimus was given for the cutaneous lesions in all patients. Systemic steroids were given in 25 patients, 1 of whom had only cutaneous involvement while 24 had pulmonary involvement with or without other extracutaneous involvement. Ten patients received hydroxychloroquine in addition to systemic steroids, while 6 patients received hydroxychloroquine alone. Among the six patients with isolated cutaneous sarcoidosis, 3 were treated with hydroxychloroquine alone while 1 received systemic steroids for unresponsive lesions and the remaining 2 were treated with topicals alone.

Follow-up

The median follow-up period was 24 months (range: 3–120). Complete resolution of the cutaneous lesions was seen in 36.8% (n = 14) with relapse in 4 of these patients on tapering steroids, lesions were in resolving phase in 13.1% (n = 5), and persistent lesions were seen in 7.8% (n = 3). Of the patients who received hydroxychloroquine alone, 4 were lost to follow up, 1 had improving cutaneous lesions, while in another the skin lesions were persistent on follow up. Of the 6 patients with isolated cutaneous sarcoidosis, 3 patients were lost to follow up, 1 had persistent lesions, while 2 had complete resolution of their skin lesions. Lung function had improved in 33% (n = 13), 8% (n = 3) had worsening, and 13% (n = 3) had relapse after stopping the steroids. Sixteen patients did not review after primary evaluation. As the study was in a tertiary care center, and patients were from distant places, the patients preferred to follow up with their local physician once the diagnosis was established, and treatment plan was made.

Discussion

Sarcoidosis has a worldwide distribution, with varying presentations and outcomes across ethnic and geographic groups. Most studies on cutaneous sarcoidosis are from the West with very little data from the other regions.[910111213] Though previously considered less common, it is being increasingly recognized in Indian patients.[356] In our study, the mean age of presentation was 48 years, consistent with that of existing literature.[31314] Females constituted only a little more than half of our patients even though most studies have shown strong female preponderance.[131516] This could be due to the gender differences in health seeking behavior in our population. The clinical features of our patients have been compared with other studies [Table 3]. There is a wide variation in the distribution as well as types of lesions across races. Majority of our patients (55.3%) had lesions over more than 1 body region, including the torso. The commonest cutaneous lesions in our study were plaques and papules as has been previously reported.[1316] Consistent with previous Indian data,[3] erythema nodosum was uncommon in our study. The other rarer types seen were psoriasiform, hypopigmented macules, scar, and angiolupoid. Owing to the polymorphic nature of cutaneous sarcoidosis lesions, it is important to be aware of the varied clinical presentations including the rarer types.
Table 3

Comparison with other studies

CharacteristicPresent studyMahajan et al., 2007[3]Collin et al., 2009[14]Ishak et al., 2014[13]Esteves et al., 2015[15]Garcia et al., 2019[16]
Number of patients382332764140
Region/EthnicityIndian sub-continentIndianWhite (57%), South Asian (28%), Afro-Caribbean (15%)LebaneseSpainCaucasian (77.5%), African (12.5%), Caribbean (5%), Asian (5%)
Mean age (± SD in years)48 (± 13)44(range 31-78)49 (range 27-84)48 (range: 19-74)52 (+/-10)54 (range 26-79)
Females (%)586574798382.5
Types of lesion in cutaneous sarcoidosis (%)Combination of papules, nodules, and plaques
 Plaques6544492230
 Papules5029295650
 Nodules13.2183930
 More than 1 morphology28.93435
Distribution of lesions (%)Widespread distribution (22/23)
 More than 1 region55.3403157.5
 Torso52.6141435
 Face44.7504642.5
 Upper limbs44.7252567.5
 Lower limbs36.8212147.5
Isolated cutaneous sarcoidosis (%)15.7297141.517.5
Systemic involvement(%)84.2712958.582.5
Extra-cutaneous organs involved (%)
 Lungs73.7527353.680
 Lymph-nodes68.41424.317.5
 Liver18.4
 Spleen13.2
 Eyes13.218
 Joints15
Comparison with other studies The prevalence of systemic involvement in cutaneous sarcoidosis varies from 29–82%.[1316] Majority (85.2%) of our patients had systemic involvement, most commonly lungs and lymph nodes, similar to that reported in a few studies.[1617] As our study was conducted in a tertiary care center, it is likely that the patients with systemic symptoms were over-represented. There was no association of the type, distribution, or number of cutaneous lesions with extracutaneous involvement or disease prognosis as reported in a previous Indian study.[3] Cutaneous sarcoidosis also has a significant variation in its histopathological findings. In contrast with existing literature,[918] classical naked granulomas described in sarcoidosis were found in only 55%. Necrosis in granuloma points toward an infective etiology, and is not classically described in sarcoidosis; however, it has been rarely reported.[9161819] Perineural localization of granulomas (seen in 1 of our cases) necessitating the exclusion of Hansen's disease, has also been noted previously in sarcoidosis.[91018] Preserved or increased reticulin staining (in 82%) is useful in diagnosing sarcoidosis since disruption of reticulin network can be found in infectious processes.[20] Even though ACE levels are neither very sensitive nor specific for the diagnosis of sarcoidosis, our study corroborated previous studies, that elevated ACE levels correlate with systemic involvement.[1415] This is the largest series of cutaneous sarcoidosis from the Indian subcontinent. The commonest clinical presentation was plaques and papules, involving more than 1 body region, including the torso. A multidisciplinary approach is important in the holistic management of this multisystem disorder.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  17 in total

1.  Cutaneous sarcoidosis: clinicopathologic study of 76 patients from Lebanon.

Authors:  Rim Ishak; Mazen Kurban; Abdul-Ghani Kibbi; Ossama Abbas
Journal:  Int J Dermatol       Date:  2014-09-30       Impact factor: 2.736

2.  Clinical spectrum and histological analysis of 32 cases of specific cutaneous sarcoidosis.

Authors:  Cristina Mangas; Maria-Teresa Fernández-Figueras; Enriqueta Fité; Natalia Fernández-Chico; Mireia Sàbat; Carlos Ferrándiz
Journal:  J Cutan Pathol       Date:  2006-12       Impact factor: 1.587

3.  Sarcoidosis in north Indian population: a retrospective study.

Authors:  Raj Kumar; Nitin Goel; S N Gaur
Journal:  Indian J Chest Dis Allied Sci       Date:  2012 Apr-Jun

Review 4.  Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease.

Authors:  Adele Haimovic; Miguel Sanchez; Marc A Judson; Stephen Prystowsky
Journal:  J Am Acad Dermatol       Date:  2012-05       Impact factor: 11.527

5.  Cutaneous sarcoidosis: clinical profile of 23 Indian patients.

Authors:  Vikram K Mahajan; Nand Lal Sharma; Ramesh Chander Sharma; Vikas C Sharma
Journal:  Indian J Dermatol Venereol Leprol       Date:  2007 Jan-Feb       Impact factor: 2.545

6.  Cutaneous sarcoidosis: a histopathological study.

Authors:  J C Cardoso; M Cravo; J P Reis; O Tellechea
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-02-26       Impact factor: 6.166

7.  The histologic spectrum of cutaneous sarcoidosis: a study of twenty-eight cases.

Authors:  Nigel J Ball; Grace T Kho; Magdalena Martinka
Journal:  J Cutan Pathol       Date:  2004-02       Impact factor: 1.587

Review 8.  Skin manifestations of sarcoidosis.

Authors:  Juan Mañá; Joaquim Marcoval
Journal:  Presse Med       Date:  2012-05-09       Impact factor: 1.228

9.  Prognostic value of skin lesions in sarcoidosis: clinical and histopathological clues.

Authors:  Tiago C Esteves; Gloria Aparicio; Berta Ferrer; Vicente Garcia-Patos
Journal:  Eur J Dermatol       Date:  2015 Nov-Dec       Impact factor: 3.328

10.  Cutaneous sarcoidosis - a great masquerader: a report of three interesting cases.

Authors:  Raghunatha R Reddy; B M Shashi Kumar; M R Harish
Journal:  Indian J Dermatol       Date:  2011 Sep-Oct       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.